[HTML][HTML] Target specificity of selective bioactive compounds in blocking α-dystroglycan receptor to suppress Lassa virus infection: an in silico approach
Lassa hemorrhagic fever, caused by Lassa mammarenavirus (LASV) infection, accumulates
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
Target specificity of selective bioactive compounds in blocking a-dystroglycan receptor to suppress Lassa virus infection: an in silico approach.
A Arefin, TI Ema, T Islam, MS Hossen… - Journal of …, 2021 - search.ebscohost.com
Lassa hemorrhagic fever, caused by Lassa mammarenavirus (LASV) infection, accumulates
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
Target specificity of selective bioactive compounds in blocking α-dystroglycan receptor to suppress Lassa virus infection: an in silico approach.
A Arefin, T Islam, S Hossen, S Al Azad… - Journal of Biomedical …, 2021 - europepmc.org
Lassa hemorrhagic fever, caused by Lassa mammarenavirus (LASV) infection, accumulates
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
Target specificity of selective bioactive compounds in blocking α-dystroglycan receptor to suppress Lassa virus infection: an in silico approach
A Arefin, TI Ema, T Islam, MS Hossen… - The Journal of …, 2021 - jbr-pub.org.cn
Lassa hemorrhagic fever, caused by Lassa mammarenavirus (LASV) infection, accumulates
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
Target specificity of selective bioactive compounds in blocking α-dystroglycan receptor to suppress Lassa virus infection: an in silico approach
A Arefin, TI Ema, T Islam, S Hossen… - Journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Lassa hemorrhagic fever, caused by Lassa mammarenavirus (LASV) infection, accumulates
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
Target specificity of selective bioactive compounds in blocking α-dystroglycan receptor to suppress Lassa virus infection: an in silico approach
A Arefin, TI Ema, T Islam, MS Hossen… - The Journal of …, 2021 - 47.56.104.122
Lassa hemorrhagic fever, caused by Lassa mammarenavirus (LASV) infection, accumulates
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
[PDF][PDF] Target specificity of selective bioactive compounds in blocking α-dystroglycan receptor to suppress Lassa virus infection: an in silico approach
S Al Azad, MNU Badal, MA Islam, P Biswas, NU Alam… - 2021 - pdfs.semanticscholar.org
Lassa hemorrhagic fever, caused by Lassa mammarenavirus (LASV) infection, accumulates
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
[PDF][PDF] Target specificity of selective bioactive compounds in blocking α-dystroglycan receptor to suppress Lassa virus infection: an in silico approach
S Al Azad, MNU Badal, MA Islam, P Biswas, NU Alam… - 2021 - researchgate.net
Lassa hemorrhagic fever, caused by Lassa mammarenavirus (LASV) infection, accumulates
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
Target specificity of selective bioactive compounds in blocking α-dystroglycan receptor to suppress Lassa virus infection: an in silico approach
A Arefin, TI Ema, T Islam, MS Hossen… - The Journal of …, 2021 - jbr-pub.org.cn
Lassa hemorrhagic fever, caused by Lassa mammarenavirus (LASV) infection, accumulates
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
Target specificity of selective bioactive compounds in blocking α-dystroglycan receptor to suppress Lassa virus infection: an in silico approach
A Arefin, TI Ema, T Islam, MS Hossen… - The Journal of …, 2021 - jbr-pub.org.cn
Lassa hemorrhagic fever, caused by Lassa mammarenavirus (LASV) infection, accumulates
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …
up to 5000 deaths every year. Currently, there is no vaccine available to combat this …